Access questions hang over Gilead’s HIV shot

October 8, 2024

Image of HIV infecting a cell

(Axios) – A new, long-acting shot to prevent HIV could represent a turning point in efforts to reduce cases around the world — if enough people can access it. Why it matters: The twice-a-year injection to prevent sexually transmitted infections is seen as more viable than a daily pre-exposure prophylaxis, or PrEP, pill, which patients frequently stop taking. (Read More)